Mirae Asset Global Investments Co. Ltd. Sells 52,815 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Mirae Asset Global Investments Co. Ltd. lowered its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 55.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 43,050 shares of the biotechnology company’s stock after selling 52,815 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Sarepta Therapeutics were worth $4,151,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. increased its holdings in shares of Sarepta Therapeutics by 0.5% in the third quarter. Vanguard Group Inc. now owns 8,572,944 shares of the biotechnology company’s stock worth $1,039,212,000 after purchasing an additional 41,465 shares during the period. Wellington Management Group LLP grew its position in Sarepta Therapeutics by 1.4% in the third quarter. Wellington Management Group LLP now owns 3,909,800 shares of the biotechnology company’s stock worth $473,946,000 after acquiring an additional 54,698 shares in the last quarter. State Street Corp grew its position in Sarepta Therapeutics by 7.9% in the second quarter. State Street Corp now owns 1,913,732 shares of the biotechnology company’s stock worth $219,161,000 after acquiring an additional 139,756 shares in the last quarter. Geode Capital Management LLC grew its position in Sarepta Therapeutics by 3.5% in the first quarter. Geode Capital Management LLC now owns 1,261,971 shares of the biotechnology company’s stock worth $173,938,000 after acquiring an additional 43,239 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD grew its position in Sarepta Therapeutics by 40.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,171,442 shares of the biotechnology company’s stock worth $161,461,000 after acquiring an additional 334,749 shares in the last quarter. Institutional investors own 86.68% of the company’s stock.

Insider Buying and Selling

In related news, Director Kathryn Jean Boor sold 761 shares of the stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $122.93, for a total value of $93,549.73. Following the completion of the transaction, the director now directly owns 7,516 shares of the company’s stock, valued at $923,941.88. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In related news, Director Kathryn Jean Boor sold 761 shares of the stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $122.93, for a total value of $93,549.73. Following the completion of the transaction, the director now directly owns 7,516 shares of the company’s stock, valued at $923,941.88. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Hans Lennart Rudolf Wigzell sold 15,000 shares of the stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $123.25, for a total transaction of $1,848,750.00. Following the completion of the transaction, the director now directly owns 22,840 shares of the company’s stock, valued at $2,815,030. The disclosure for this sale can be found here. Insiders sold a total of 22,096 shares of company stock valued at $2,739,419 over the last three months. Corporate insiders own 7.40% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. Evercore ISI upped their target price on shares of Sarepta Therapeutics from $108.00 to $138.00 and gave the stock an “in-line” rating in a research report on Tuesday, February 20th. UBS Group upped their target price on shares of Sarepta Therapeutics from $164.00 to $167.00 and gave the stock a “buy” rating in a research report on Friday, March 1st. Needham & Company LLC cut their target price on shares of Sarepta Therapeutics from $169.00 to $166.00 and set a “buy” rating for the company in a research report on Thursday, February 29th. Barclays upped their price target on shares of Sarepta Therapeutics from $141.00 to $185.00 and gave the company an “overweight” rating in a research report on Thursday, February 29th. Finally, Royal Bank of Canada upped their price target on shares of Sarepta Therapeutics from $151.00 to $157.00 and gave the company an “outperform” rating in a research report on Thursday, February 29th. Four research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $158.38.

Sarepta Therapeutics Stock Performance

Sarepta Therapeutics stock opened at $118.31 on Tuesday. The company has a current ratio of 3.95, a quick ratio of 3.45 and a debt-to-equity ratio of 1.32. The firm has a 50-day moving average of $127.31 and a 200-day moving average of $110.37. The firm has a market cap of $11.11 billion, a P/E ratio of -19.33 and a beta of 0.94. Sarepta Therapeutics, Inc. has a 1-year low of $55.25 and a 1-year high of $159.89.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Wednesday, February 28th. The biotechnology company reported $0.47 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.50. Sarepta Therapeutics had a negative net margin of 43.11% and a negative return on equity of 18.97%. The company had revenue of $396.80 million during the quarter, compared to analyst estimates of $387.18 million. During the same period in the prior year, the business posted ($1.24) earnings per share. Sarepta Therapeutics’s revenue for the quarter was up 53.6% on a year-over-year basis. Sell-side analysts expect that Sarepta Therapeutics, Inc. will post 2.14 EPS for the current year.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.